Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CERT 
Certara Inc (CERT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: CERT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $14.11
1 Year Target Price $14.11
| 4 | Strong Buy |
| 1 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.21% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.80B USD | Price to earnings Ratio 224.4 | 1Y Target Price 14.11 |
Price to earnings Ratio 224.4 | 1Y Target Price 14.11 | ||
Volume (30-day avg) 11 | Beta 1.43 | 52 Weeks Range 8.63 - 15.69 | Updated Date 09/16/2025 |
52 Weeks Range 8.63 - 15.69 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 1.97% | Operating Margin (TTM) 4.97% |
Management Effectiveness
Return on Assets (TTM) 1.31% | Return on Equity (TTM) 0.75% |
Valuation
Trailing PE 224.4 | Forward PE 22.57 | Enterprise Value 1953103982 | Price to Sales(TTM) 4.44 |
Enterprise Value 1953103982 | Price to Sales(TTM) 4.44 | ||
Enterprise Value to Revenue 4.81 | Enterprise Value to EBITDA 18.86 | Shares Outstanding 160624000 | Shares Floating 120276543 |
Shares Outstanding 160624000 | Shares Floating 120276543 | ||
Percent Insiders 2.48 | Percent Institutions 104.2 |
Upturn AI SWOT
Certara Inc
Company Overview
History and Background
Certara, Inc. was founded in 2008 through the merger of Pharsight Corporation and Tripos International. The company has grown through acquisitions and organic development, becoming a leading provider of biosimulation software and services.
Core Business Areas
- Model-Informed Drug Development (MIDD): Provides software and services that use modeling and simulation to improve drug development decision-making.
- Regulatory Science: Offers consulting and services to navigate regulatory pathways and optimize submissions.
- Market Access: Provides services to demonstrate the value of drugs and gain market access.
Leadership and Structure
Certara is led by a CEO and a management team responsible for various functions. The company has a board of directors overseeing strategy and governance.
Top Products and Market Share
Key Offerings
- MarketShare: 0.4
- Phoenix: A software platform for pharmacokinetic (PK) and pharmacodynamic (PD) modeling and simulation. Certara holds a significant market share (estimated 40% based on industry reports) in PK/PD modeling software. Competitors: NONMEM, Monolix.
- MarketShare: 0.5
- Simcyp: A physiologically based pharmacokinetic (PBPK) modeling and simulation platform. The drug-drug interaction module is very popular and is being used by major companies in the industry. This module has the capability of prediction of the in-vivo drug interactions. Certara holds a significant market share (estimated 50% based on industry reports) in PBPK modeling. Competitors: GastroPlus, PK-Sim.
Market Dynamics
Industry Overview
The biopharmaceutical industry increasingly relies on modeling and simulation to improve drug development efficiency, reduce costs, and increase success rates. This is driven by regulatory requirements (FDA), scientific advancements, and the growing complexity of drug development.
Positioning
Certara is positioned as a leading provider of biosimulation software and services, with a comprehensive portfolio of solutions and a strong reputation in the industry. The company benefits from its integrated offering and its expertise in regulatory science.
Total Addressable Market (TAM)
The TAM for biosimulation software and services is estimated at $5 billion. Certara is well-positioned to capture a significant share of this market given its current offerings.
Upturn SWOT Analysis
Strengths
- Strong market position
- Comprehensive product portfolio
- Deep scientific expertise
- Established relationships with regulatory agencies
Weaknesses
- Reliance on biopharmaceutical industry
- Potential for competition from internal development
- Integration risks from acquisitions
Opportunities
- Growing demand for biosimulation
- Expansion into new therapeutic areas
- Increased regulatory acceptance of biosimulation
- Potential for strategic partnerships
Threats
- Economic downturn impacting biopharmaceutical spending
- Emergence of disruptive technologies
- Increased competition from larger software companies
- Changes in regulatory requirements
Competitors and Market Share
Key Competitors
- MSFT
- Dassault Systemes (DSY.PA)
Competitive Landscape
Certara's advantages include its focus on biosimulation, its comprehensive product portfolio, and its deep scientific expertise. Disadvantages include competition from larger software companies and reliance on the biopharmaceutical industry.
Major Acquisitions
BaseCase
- Year: 2018
- Acquisition Price (USD millions): 78.7
- Strategic Rationale: Expanded Certara's market access capabilities.
Growth Trajectory and Initiatives
Historical Growth: Certara has achieved growth through organic expansion and acquisitions.
Future Projections: Analysts project continued revenue growth in the coming years, driven by the increasing adoption of biosimulation.
Recent Initiatives: Recent initiatives include expanding its offerings, enhancing its technology platform, and forming strategic partnerships.
Summary
Certara demonstrates strength with a comprehensive biosimulation portfolio and growing revenues. However, fluctuations in net income and reliance on the biopharmaceutical industry pose risks. Strategic acquisitions and expansion initiatives appear promising. Monitoring competition and economic conditions are essential for maintaining growth and profitability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Analyst Reports
- Industry Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share estimates are based on industry reports and may vary. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Certara Inc
Exchange NASDAQ | Headquaters Radnor, PA, United States | ||
IPO Launch date 2020-12-11 | CEO & Director Dr. William F. Feehery Ph.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 1487 | Website https://www.certara.com |
Full time employees 1487 | Website https://www.certara.com | ||
Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines; Chemaxon Compound Registration, that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.